Christopher Gignoux
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 55 | 2026 | 1406 | 3.660 |
Why?
| | Genetics, Population | 34 | 2026 | 214 | 3.370 |
Why?
| | Polymorphism, Single Nucleotide | 66 | 2026 | 2145 | 2.490 |
Why?
| | Genomics | 22 | 2026 | 834 | 2.000 |
Why?
| | Genome, Human | 25 | 2025 | 422 | 1.850 |
Why?
| | Genetic Predisposition to Disease | 34 | 2026 | 2363 | 1.790 |
Why?
| | Multifactorial Inheritance | 17 | 2026 | 202 | 1.750 |
Why?
| | Genetic Variation | 18 | 2025 | 983 | 1.640 |
Why?
| | Models, Genetic | 14 | 2026 | 536 | 1.390 |
Why?
| | Asthma | 21 | 2026 | 1767 | 1.240 |
Why?
| | Precision Medicine | 5 | 2026 | 457 | 1.090 |
Why?
| | Transcriptome | 8 | 2026 | 1045 | 1.040 |
Why?
| | Haplotypes | 23 | 2025 | 490 | 0.910 |
Why?
| | Genetics, Medical | 5 | 2023 | 23 | 0.860 |
Why?
| | Biological Specimen Banks | 6 | 2026 | 102 | 0.800 |
Why?
| | Gene Frequency | 14 | 2026 | 481 | 0.770 |
Why?
| | Pharmacogenetics | 2 | 2021 | 172 | 0.740 |
Why?
| | Gastritis | 1 | 2023 | 115 | 0.710 |
Why?
| | Enteritis | 1 | 2023 | 103 | 0.710 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.670 |
Why?
| | Humans | 145 | 2026 | 144759 | 0.660 |
Why?
| | Human Migration | 6 | 2021 | 25 | 0.610 |
Why?
| | Quantitative Trait Loci | 8 | 2026 | 374 | 0.580 |
Why?
| | Gene Flow | 8 | 2020 | 85 | 0.580 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 8 | 0.570 |
Why?
| | Smad2 Protein | 1 | 2018 | 37 | 0.570 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 330 | 0.570 |
Why?
| | Genotype | 24 | 2025 | 1833 | 0.560 |
Why?
| | Phenotype | 17 | 2026 | 3162 | 0.520 |
Why?
| | Pedigree | 4 | 2025 | 514 | 0.520 |
Why?
| | Software | 4 | 2026 | 690 | 0.500 |
Why?
| | Thyroid Neoplasms | 3 | 2026 | 345 | 0.500 |
Why?
| | Gene Expression Profiling | 7 | 2026 | 1782 | 0.470 |
Why?
| | Chromosome Mapping | 11 | 2023 | 510 | 0.460 |
Why?
| | DNA Methylation | 5 | 2025 | 681 | 0.450 |
Why?
| | Population | 2 | 2014 | 30 | 0.450 |
Why?
| | Population Growth | 2 | 2012 | 12 | 0.440 |
Why?
| | DNA, Mitochondrial | 6 | 2016 | 211 | 0.440 |
Why?
| | Metagenomics | 4 | 2023 | 181 | 0.420 |
Why?
| | Indians, North American | 7 | 2021 | 647 | 0.400 |
Why?
| | Obesity | 5 | 2025 | 3077 | 0.400 |
Why?
| | Receptors, KIR | 5 | 2022 | 110 | 0.400 |
Why?
| | Mexican Americans | 7 | 2023 | 114 | 0.400 |
Why?
| | Agriculture | 2 | 2011 | 104 | 0.380 |
Why?
| | Evolution, Molecular | 6 | 2021 | 514 | 0.380 |
Why?
| | Genetic Loci | 7 | 2019 | 261 | 0.360 |
Why?
| | Exome | 5 | 2022 | 227 | 0.350 |
Why?
| | Female | 59 | 2026 | 78271 | 0.350 |
Why?
| | Molecular Epidemiology | 3 | 2023 | 73 | 0.320 |
Why?
| | Alleles | 12 | 2025 | 879 | 0.320 |
Why?
| | Indians, South American | 2 | 2020 | 23 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2026 | 409 | 0.310 |
Why?
| | Case-Control Studies | 14 | 2026 | 3604 | 0.310 |
Why?
| | Nasal Mucosa | 2 | 2025 | 112 | 0.310 |
Why?
| | Genetic Association Studies | 3 | 2022 | 372 | 0.310 |
Why?
| | Male | 55 | 2026 | 72315 | 0.300 |
Why?
| | Population Groups | 2 | 2020 | 58 | 0.300 |
Why?
| | Computational Biology | 3 | 2023 | 680 | 0.290 |
Why?
| | Linkage Disequilibrium | 9 | 2023 | 246 | 0.290 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 684 | 0.290 |
Why?
| | Gene Expression Regulation | 3 | 2026 | 2608 | 0.270 |
Why?
| | Proteome | 2 | 2024 | 518 | 0.270 |
Why?
| | Skin Pigmentation | 2 | 2018 | 48 | 0.270 |
Why?
| | Kidney Diseases | 2 | 2025 | 427 | 0.270 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2168 | 0.270 |
Why?
| | Risk Factors | 19 | 2025 | 10779 | 0.270 |
Why?
| | Selection, Genetic | 4 | 2019 | 256 | 0.260 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 180 | 0.250 |
Why?
| | Receptors, KIR2DL1 | 2 | 2018 | 21 | 0.250 |
Why?
| | Genetic Markers | 7 | 2023 | 331 | 0.250 |
Why?
| | Colorectal Neoplasms | 2 | 2025 | 845 | 0.240 |
Why?
| | Mexico | 8 | 2023 | 233 | 0.240 |
Why?
| | Phylogeography | 5 | 2020 | 55 | 0.240 |
Why?
| | Data Compression | 1 | 2026 | 8 | 0.240 |
Why?
| | Environmental Exposure | 3 | 2017 | 588 | 0.240 |
Why?
| | Body Mass Index | 5 | 2025 | 2438 | 0.230 |
Why?
| | Colorado | 4 | 2024 | 4564 | 0.230 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2025 | 14 | 0.230 |
Why?
| | Thyroid Diseases | 1 | 2026 | 43 | 0.230 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 17 | 0.230 |
Why?
| | Minority Groups | 2 | 2019 | 282 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 2583 | 0.230 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 40 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2023 | 947 | 0.230 |
Why?
| | Algorithms | 4 | 2025 | 1837 | 0.220 |
Why?
| | RNA Splicing | 1 | 2026 | 284 | 0.210 |
Why?
| | Puerto Rico | 8 | 2021 | 58 | 0.210 |
Why?
| | Phylogeny | 7 | 2022 | 1016 | 0.210 |
Why?
| | Killer Cells, Natural | 4 | 2021 | 467 | 0.210 |
Why?
| | Bivalvia | 1 | 2024 | 7 | 0.210 |
Why?
| | Computer Simulation | 7 | 2026 | 1025 | 0.210 |
Why?
| | Heterozygote | 3 | 2021 | 315 | 0.210 |
Why?
| | Chromosomes, Human, Pair 6 | 3 | 2014 | 46 | 0.200 |
Why?
| | Genes, MHC Class I | 2 | 2021 | 36 | 0.200 |
Why?
| | Longevity | 1 | 2025 | 173 | 0.200 |
Why?
| | Aged | 16 | 2025 | 25913 | 0.200 |
Why?
| | Triglycerides | 3 | 2025 | 520 | 0.200 |
Why?
| | Thyroid Nodule | 1 | 2024 | 56 | 0.190 |
Why?
| | Long QT Syndrome | 1 | 2024 | 69 | 0.190 |
Why?
| | United Kingdom | 4 | 2026 | 338 | 0.190 |
Why?
| | Young Adult | 12 | 2022 | 14105 | 0.190 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 253 | 0.190 |
Why?
| | Glaucoma, Open-Angle | 1 | 2024 | 104 | 0.190 |
Why?
| | Proteins | 2 | 2022 | 1021 | 0.180 |
Why?
| | Receptors, KIR3DS1 | 1 | 2022 | 7 | 0.180 |
Why?
| | Receptors, KIR3DL1 | 1 | 2022 | 20 | 0.180 |
Why?
| | Immunoglobulin E | 2 | 2014 | 315 | 0.180 |
Why?
| | Middle Aged | 19 | 2025 | 35875 | 0.180 |
Why?
| | C-Reactive Protein | 1 | 2024 | 416 | 0.180 |
Why?
| | Demography | 5 | 2018 | 288 | 0.170 |
Why?
| | Emigration and Immigration | 3 | 2013 | 66 | 0.170 |
Why?
| | Jews | 1 | 2021 | 20 | 0.170 |
Why?
| | Collagen Type VII | 1 | 2021 | 28 | 0.170 |
Why?
| | Myocardial Ischemia | 1 | 2023 | 285 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2025 | 281 | 0.170 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 33 | 0.170 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 2021 | 42 | 0.170 |
Why?
| | History, Medieval | 3 | 2021 | 47 | 0.170 |
Why?
| | Uterine Hemorrhage | 1 | 2021 | 41 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2025 | 780 | 0.170 |
Why?
| | Drug Implants | 1 | 2021 | 83 | 0.170 |
Why?
| | Electrocardiography | 1 | 2024 | 662 | 0.160 |
Why?
| | Adult | 20 | 2025 | 40449 | 0.160 |
Why?
| | Eosinophilia | 1 | 2023 | 221 | 0.160 |
Why?
| | Indians, Central American | 1 | 2020 | 6 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 710 | 0.160 |
Why?
| | Population Health | 1 | 2021 | 44 | 0.160 |
Why?
| | Latin America | 2 | 2018 | 94 | 0.160 |
Why?
| | CpG Islands | 3 | 2025 | 165 | 0.160 |
Why?
| | Adiposity | 1 | 2025 | 543 | 0.160 |
Why?
| | Reference Standards | 1 | 2020 | 177 | 0.160 |
Why?
| | Adolescent | 18 | 2021 | 22428 | 0.150 |
Why?
| | Adaptation, Biological | 1 | 2020 | 52 | 0.150 |
Why?
| | Pre-Eclampsia | 1 | 2022 | 204 | 0.150 |
Why?
| | Self Report | 2 | 2021 | 872 | 0.150 |
Why?
| | Lipase | 1 | 2020 | 75 | 0.150 |
Why?
| | Principal Component Analysis | 2 | 2026 | 197 | 0.150 |
Why?
| | Human Genetics | 1 | 2019 | 3 | 0.150 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 372 | 0.150 |
Why?
| | Apolipoprotein L1 | 1 | 2018 | 14 | 0.150 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 758 | 0.150 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 365 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1129 | 0.140 |
Why?
| | Geographic Mapping | 1 | 2019 | 29 | 0.140 |
Why?
| | United States | 16 | 2025 | 15966 | 0.140 |
Why?
| | Antiporters | 1 | 2018 | 22 | 0.140 |
Why?
| | Europe | 5 | 2020 | 412 | 0.140 |
Why?
| | Liver Diseases | 1 | 2021 | 304 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2023 | 741 | 0.140 |
Why?
| | Primates | 1 | 2019 | 132 | 0.140 |
Why?
| | HLA-C Antigens | 1 | 2018 | 36 | 0.140 |
Why?
| | Chromosomes, Human, Y | 2 | 2008 | 36 | 0.130 |
Why?
| | Dermatitis, Atopic | 1 | 2021 | 321 | 0.130 |
Why?
| | Collagen Diseases | 1 | 2017 | 8 | 0.130 |
Why?
| | Fibrillar Collagens | 1 | 2017 | 14 | 0.130 |
Why?
| | Databases, Genetic | 3 | 2026 | 248 | 0.130 |
Why?
| | Microbiota | 2 | 2023 | 781 | 0.130 |
Why?
| | Epistasis, Genetic | 1 | 2017 | 66 | 0.130 |
Why?
| | Apolipoprotein A-V | 1 | 2017 | 4 | 0.130 |
Why?
| | Gene Pool | 2 | 2013 | 4 | 0.130 |
Why?
| | Weight Gain | 1 | 2021 | 556 | 0.130 |
Why?
| | History, Ancient | 3 | 2013 | 55 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1495 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 310 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 266 | 0.130 |
Why?
| | Saliva | 2 | 2020 | 249 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2878 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2021 | 1095 | 0.120 |
Why?
| | Homozygote | 3 | 2023 | 199 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 885 | 0.120 |
Why?
| | Language | 2 | 2011 | 321 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1135 | 0.110 |
Why?
| | Colombia | 3 | 2021 | 42 | 0.110 |
Why?
| | Social Class | 2 | 2013 | 268 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5868 | 0.110 |
Why?
| | Genealogy and Heraldry | 1 | 2013 | 3 | 0.100 |
Why?
| | Africa, Southern | 3 | 2018 | 6 | 0.100 |
Why?
| | Minority Health | 1 | 2013 | 18 | 0.100 |
Why?
| | Health Surveys | 1 | 2016 | 518 | 0.100 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 23 | 0.100 |
Why?
| | Premature Birth | 1 | 2018 | 380 | 0.100 |
Why?
| | Population Dynamics | 2 | 2012 | 158 | 0.100 |
Why?
| | Urban Health | 1 | 2013 | 96 | 0.100 |
Why?
| | Search Engine | 1 | 2013 | 12 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2020 | 1166 | 0.100 |
Why?
| | Albuterol | 1 | 2013 | 73 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 40 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 157 | 0.100 |
Why?
| | Neanderthals | 1 | 2013 | 13 | 0.100 |
Why?
| | Forced Expiratory Volume | 2 | 2013 | 449 | 0.100 |
Why?
| | Child | 15 | 2020 | 22633 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 462 | 0.090 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2012 | 26 | 0.090 |
Why?
| | Carrier Proteins | 1 | 2017 | 737 | 0.090 |
Why?
| | Kallikreins | 1 | 2012 | 25 | 0.090 |
Why?
| | HLA-DQ beta-Chains | 1 | 2012 | 57 | 0.090 |
Why?
| | Mutation | 5 | 2018 | 4089 | 0.090 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 182 | 0.090 |
Why?
| | Air Pollution | 1 | 2016 | 327 | 0.090 |
Why?
| | Biological Evolution | 2 | 2019 | 488 | 0.090 |
Why?
| | Respiratory Function Tests | 2 | 2012 | 547 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 161 | 0.090 |
Why?
| | HLA-B Antigens | 2 | 2022 | 56 | 0.090 |
Why?
| | History, 17th Century | 1 | 2011 | 14 | 0.090 |
Why?
| | History, 15th Century | 1 | 2011 | 10 | 0.090 |
Why?
| | History, 18th Century | 1 | 2011 | 16 | 0.090 |
Why?
| | Polynesia | 2 | 2021 | 3 | 0.090 |
Why?
| | Tuberculosis | 1 | 2014 | 291 | 0.080 |
Why?
| | Anthropometry | 2 | 2025 | 200 | 0.080 |
Why?
| | Cluster Analysis | 3 | 2023 | 521 | 0.080 |
Why?
| | History, 19th Century | 1 | 2011 | 61 | 0.080 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 334 | 0.080 |
Why?
| | Chile | 2 | 2021 | 26 | 0.080 |
Why?
| | Respiratory Sounds | 1 | 2011 | 105 | 0.080 |
Why?
| | Lung | 2 | 2016 | 4109 | 0.080 |
Why?
| | Body Height | 2 | 2023 | 202 | 0.080 |
Why?
| | Cohort Studies | 5 | 2026 | 5960 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2014 | 2452 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 161 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 269 | 0.080 |
Why?
| | History, 21st Century | 1 | 2011 | 219 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 325 | 0.080 |
Why?
| | Genotyping Techniques | 2 | 2020 | 69 | 0.080 |
Why?
| | Machine Learning | 2 | 2025 | 585 | 0.080 |
Why?
| | South Africa | 3 | 2015 | 261 | 0.080 |
Why?
| | Peru | 2 | 2022 | 62 | 0.070 |
Why?
| | Vital Capacity | 1 | 2010 | 290 | 0.070 |
Why?
| | Electronic Health Records | 3 | 2021 | 1173 | 0.070 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2019 | 38 | 0.070 |
Why?
| | Africa | 3 | 2017 | 116 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1455 | 0.070 |
Why?
| | South America | 2 | 2020 | 57 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 920 | 0.070 |
Why?
| | Life Style | 2 | 2022 | 479 | 0.070 |
Why?
| | Americas | 2 | 2018 | 26 | 0.070 |
Why?
| | Signal Transduction | 2 | 2019 | 5226 | 0.070 |
Why?
| | Risk | 3 | 2018 | 911 | 0.070 |
Why?
| | Ants | 1 | 2007 | 27 | 0.070 |
Why?
| | Linguistics | 1 | 2007 | 27 | 0.060 |
Why?
| | Odds Ratio | 3 | 2014 | 1075 | 0.060 |
Why?
| | Bayes Theorem | 2 | 2024 | 433 | 0.060 |
Why?
| | Whole Genome Sequencing | 2 | 2018 | 182 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2019 | 55 | 0.060 |
Why?
| | Speech | 1 | 2007 | 77 | 0.060 |
Why?
| | Human Genome Project | 2 | 2017 | 15 | 0.060 |
Why?
| | Organ Specificity | 1 | 2026 | 312 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2025 | 40 | 0.060 |
Why?
| | Mendelian Randomization Analysis | 1 | 2025 | 55 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2025 | 10 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 787 | 0.060 |
Why?
| | Bias | 2 | 2019 | 202 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2025 | 47 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 549 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3890 | 0.060 |
Why?
| | Base Sequence | 3 | 2016 | 2190 | 0.050 |
Why?
| | Body Size | 1 | 2025 | 95 | 0.050 |
Why?
| | RNA | 1 | 2011 | 940 | 0.050 |
Why?
| | Phenethylamines | 1 | 2024 | 19 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 164 | 0.050 |
Why?
| | Torsades de Pointes | 1 | 2024 | 23 | 0.050 |
Why?
| | Argentina | 2 | 2015 | 30 | 0.050 |
Why?
| | Child, Preschool | 6 | 2020 | 11787 | 0.050 |
Why?
| | Microsatellite Repeats | 3 | 2011 | 157 | 0.050 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 612 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 442 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 614 | 0.050 |
Why?
| | Prevalence | 2 | 2025 | 2834 | 0.050 |
Why?
| | Iran | 1 | 2023 | 44 | 0.050 |
Why?
| | Los Angeles | 1 | 2023 | 76 | 0.050 |
Why?
| | Geography | 2 | 2016 | 203 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2026 | 573 | 0.050 |
Why?
| | Biology | 1 | 2024 | 91 | 0.050 |
Why?
| | Caribbean Region | 2 | 2013 | 30 | 0.050 |
Why?
| | Lipoprotein(a) | 1 | 2023 | 68 | 0.050 |
Why?
| | Minisatellite Repeats | 1 | 2002 | 36 | 0.050 |
Why?
| | Factor X | 1 | 2022 | 25 | 0.050 |
Why?
| | Factor VII | 1 | 2022 | 25 | 0.050 |
Why?
| | Genes | 1 | 2002 | 226 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2025 | 318 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 3333 | 0.040 |
Why?
| | Blood Coagulation Factors | 1 | 2022 | 55 | 0.040 |
Why?
| | Epigenomics | 1 | 2022 | 114 | 0.040 |
Why?
| | Genes, Recessive | 1 | 2021 | 78 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2021 | 44 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2021 | 52 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2021 | 46 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 459 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 163 | 0.040 |
Why?
| | Bronchi | 2 | 2014 | 267 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2020 | 6429 | 0.040 |
Why?
| | Genome, Viral | 1 | 2022 | 218 | 0.040 |
Why?
| | Central America | 1 | 2020 | 25 | 0.040 |
Why?
| | Models, Statistical | 1 | 2025 | 681 | 0.040 |
Why?
| | China | 1 | 2021 | 269 | 0.040 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2020 | 18 | 0.040 |
Why?
| | Sulfonamides | 1 | 2024 | 580 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 249 | 0.040 |
Why?
| | Acyltransferases | 1 | 2020 | 78 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 770 | 0.040 |
Why?
| | Infant | 3 | 2021 | 10034 | 0.040 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.040 |
Why?
| | Topography, Medical | 1 | 2019 | 11 | 0.040 |
Why?
| | Asia, Northern | 1 | 2018 | 1 | 0.040 |
Why?
| | Mongolia | 1 | 2018 | 7 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1985 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2947 | 0.040 |
Why?
| | Classification | 1 | 2019 | 43 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2018 | 39 | 0.040 |
Why?
| | Animals | 6 | 2024 | 38058 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 62 | 0.030 |
Why?
| | Receptors, Natural Killer Cell | 1 | 2018 | 16 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8265 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 148 | 0.030 |
Why?
| | Hominidae | 1 | 2019 | 87 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 473 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 78 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 570 | 0.030 |
Why?
| | New York City | 1 | 2017 | 89 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 965 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3409 | 0.030 |
Why?
| | DNA | 1 | 2024 | 1463 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1137 | 0.030 |
Why?
| | Multigene Family | 1 | 2017 | 204 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 129 | 0.030 |
Why?
| | DNA, Intergenic | 1 | 2016 | 29 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2014 | 2930 | 0.030 |
Why?
| | Parents | 1 | 2025 | 1403 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 62 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2496 | 0.030 |
Why?
| | Musculoskeletal Diseases | 1 | 2017 | 88 | 0.030 |
Why?
| | Prospective Studies | 3 | 2014 | 7990 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2019 | 377 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | Ligands | 1 | 2018 | 673 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3671 | 0.030 |
Why?
| | Sexism | 1 | 2016 | 70 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2017 | 154 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 321 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 946 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 478 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 780 | 0.030 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2014 | 16 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 21 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2019 | 2155 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2014 | 124 | 0.030 |
Why?
| | San Francisco | 1 | 2013 | 60 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 88 | 0.030 |
Why?
| | HapMap Project | 1 | 2013 | 4 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 650 | 0.030 |
Why?
| | Biomarkers | 1 | 2025 | 4271 | 0.030 |
Why?
| | Africa, Northern | 1 | 2013 | 4 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1618 | 0.020 |
Why?
| | Mammography | 1 | 2014 | 166 | 0.020 |
Why?
| | Blood Glucose | 1 | 2023 | 2327 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2112 | 0.020 |
Why?
| | Interleukin-13 | 1 | 2014 | 144 | 0.020 |
Why?
| | Skin Tests | 1 | 2013 | 94 | 0.020 |
Why?
| | Databases, Factual | 1 | 2019 | 1486 | 0.020 |
Why?
| | Th2 Cells | 1 | 2014 | 171 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 508 | 0.020 |
Why?
| | HLA Antigens | 1 | 2014 | 225 | 0.020 |
Why?
| | Hawaii | 1 | 2012 | 46 | 0.020 |
Why?
| | Genome, Mitochondrial | 1 | 2012 | 29 | 0.020 |
Why?
| | Income | 1 | 2013 | 202 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2273 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 58 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 174 | 0.020 |
Why?
| | Markov Chains | 1 | 2012 | 129 | 0.020 |
Why?
| | Boston | 1 | 2011 | 92 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2014 | 457 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 406 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 467 | 0.020 |
Why?
| | Air Pollutants | 1 | 2016 | 438 | 0.020 |
Why?
| | Angola | 1 | 2011 | 1 | 0.020 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 23 | 0.020 |
Why?
| | Canada | 1 | 2012 | 428 | 0.020 |
Why?
| | Mozambique | 1 | 2011 | 7 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Africa South of the Sahara | 1 | 2011 | 53 | 0.020 |
Why?
| | Insurance, Health | 1 | 2013 | 302 | 0.020 |
Why?
| | North America | 1 | 2011 | 310 | 0.020 |
Why?
| | Culture | 1 | 2011 | 125 | 0.020 |
Why?
| | Allergens | 1 | 2013 | 384 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 284 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 427 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2011 | 200 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 7173 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7190 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 797 | 0.020 |
Why?
| | Hypersensitivity | 1 | 2011 | 252 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 73 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2117 | 0.020 |
Why?
| | Social Behavior | 1 | 2011 | 288 | 0.020 |
Why?
| | Family | 1 | 2013 | 679 | 0.020 |
Why?
| | Inbreeding | 1 | 2007 | 20 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 854 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1313 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1499 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3540 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1741 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 594 | 0.010 |
Why?
| | Reproduction | 1 | 2007 | 207 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1821 | 0.010 |
Why?
| | Smoking | 1 | 2012 | 1472 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2925 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2002 | 28 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2002 | 39 | 0.010 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2002 | 39 | 0.010 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2002 | 46 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 329 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6048 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18339 | 0.010 |
Why?
|
|
Gignoux's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|